Related references
Note: Only part of the references are listed.The Cardiovascular Effects of GLP-1 Receptor Agonists
Theodore Okerson et al.
CARDIOVASCULAR THERAPEUTICS (2012)
Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With a Thiazolidinedione Alone or in Combination With Metformin for 2 Years
Paul Norwood et al.
CLINICAL THERAPEUTICS (2012)
Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme
B. Zinman et al.
DIABETES OBESITY & METABOLISM (2012)
Exenatide Once Weekly for the Treatment of Type 2 Diabetes Mellitus: Clinical Results in Subgroups of Patients Using Different Concomitant Medications
Richard Pencek et al.
POSTGRADUATE MEDICINE (2012)
Cardiovascular Comorbidities of Type 2 Diabetes Mellitus: Defining the Potential of Glucagonlike peptide-1-Based Therapies
Robert Chilton et al.
AMERICAN JOURNAL OF MEDICINE (2011)
Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes
Robert Ratner et al.
CARDIOVASCULAR DIABETOLOGY (2011)
Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting
Richard M. Bergenstal et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2-3 liraglutide clinical development studies
Steven P. Marso et al.
DIABETES & VASCULAR DISEASE RESEARCH (2011)
Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies A retrospective analysis of the LifeLink database
Jennie H. Best et al.
DIABETES CARE (2011)
Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events: A Meta-Analysis of Randomized Clinical Trials
Matteo Monami et al.
EXPERIMENTAL DIABETES RESEARCH (2011)
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
Michaela Diamant et al.
LANCET (2010)
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
Richard M. Bergenstal et al.
LANCET (2010)
Diabetes Prevalence and Therapeutic Target Achievement in the United States, 1999 to 2006
Bernard M. Y. Cheung et al.
AMERICAN JOURNAL OF MEDICINE (2009)
Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting
D. I. Brixner et al.
DIABETES OBESITY & METABOLISM (2009)
Improved Glycemic Control and Reduction of Cardiometabolic Risk Factors in Subjects with Type 2 Diabetes and Metabolic Syndrome Treated with Exenatide in a Clinical Practice Setting
Rajat Bhushan et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2009)
Insights from the Liraglutide Clinical Development Program-the Liraglutide Effect and Action in Diabetes (LEAD) Studies
Janet B. McGill
POSTGRADUATE MEDICINE (2009)
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Daniel J. Drucker et al.
LANCET (2008)
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
David C. Klonoff et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients
Giovanni Targher et al.
DIABETES CARE (2007)
Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease
Masahide Hamaguchi et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2007)
Primary prevention of cardiovascular diseases in people with diabetes mellitus - A scientific statement from the American Heart Association and the American Diabetes Association
John B. Buse et al.
DIABETES CARE (2007)
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes
L. Blonde et al.
DIABETES OBESITY & METABOLISM (2006)
Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus
R. E. Ratner et al.
DIABETES OBESITY & METABOLISM (2006)
Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia
KB Degn et al.
DIABETES (2004)
Share Paper
